Spyre says SPY003 shows statistically significant RHI reduction at Week 12
Spyre’s SPY003 (anti-IL-23) met its primary endpoint with a statistically significant 10.0-point reduction in Robart’s Histopathology Index score versus baseline at Week 12 (p<0.0001).
0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) scoreSecondary endpoints included clinical remission by modified Mayo Score of 20% and endoscopic improvement of 30%SPY003 was well to…